Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' innovative platform allows for the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering in one-step. The resulting ADCs have a well-defined drug-to-antibody ratio, are stable and monomeric. All these favorable properties contribute to the high efficacy, stability and low level of toxicity observed so far. In summary, the straightforward drug conjugation, versatility of the technology and high in vivo efficacy enable the generation of ADC compounds for the treatment of patients with a high unmet medical need. For more information, please visit www.ararisbiotech.com.